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Steroids are an important class of multi-cyclic compounds that
exhibit multiple pharmacological and physiological activities
in living organisms. Interestingly many of them have shown
promising biological activities such as antimicrobial (Lone
et al., 2013; Salmi et al., 2008; Gogoi et al., 2012; Kakati et al.,
2013; Krishnamurthy et al., 1998), antioxidant (Prokai-Tatrai
et al., 2008; Mooradian, 1993), anti-inﬂammatory (Mohamed
et al., 2012; Maitraie et al., 2009), anti-mitotic (Rao et al.,
2002), cytotoxic (Mayer and Bracher, 2011; Shan et al., 2009)
and anticancer (Fernandez-Herrera et al., 2012) activities. Inrecent years, many cholesterol heterocyclic derivatives have
exhibited antibacterial and antifungal activities (Loncle et al.,
2004; Brunel et al., 2005). Banday et al. reported that fatty acid
analogues of cholesterol have shown better antimicrobial activ-
ities (Banday et al., 2010) (Fig. 1) and Bildziukevich et al. dis-
closed the cytotoxicity of cholesteryl ester derivatives
(Bildziukevich et al., 2013) (Fig. 1). A number of the simple ben-
zamides (Carpino et al., 1983; Chambhare, 2003; Moreno et al.,
2010) (Fig. 2) and sulphonamides (Aslan et al., 2012; Kamal
et al., 2013; Basanagouda et al., 2010) (Fig. 2) were revealed as
potent antibacterial agents. With the knowledge of these previ-
ous reports available in the literature, we inspired to study
in vitro anti-bacterial and anti-fungal activities of carboxamide,
sulphonamide, carbamate, urea and thiourea derived from gly-
cinate and carbonate derivatives of cholesterol and the results
were presented here.
The hydroxyl group attached with ring A in cholesterol has
been derived to glycinates and carbonates by the use of cou-
pling agent (Paul and Anderson, 1960). The cholesteryl glyci-
nates (Ha et al., 2011; Li et al., 2006) and carbonates
derivatives were further built up to simple amides (Luo
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Figure 1 Examples for ester derivatives of cholesterol shown biological activities.
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Figure 2 Examples for simple amide and sulphonamide based
antibiotics.
Evaluation of antimicrobial activity of glycinate and carbonate derivatives of cholesterol 659et al., 2001; De Logu et al., 2009), sulphonamide (Reddy et al.,
2013; Ozbek et al., 2007; Keche et al., 2012), urea (Zhao et al.,
2013; Faidallah et al., 2011; Vega-Perez et al., 2012) and
thiourea (Hearn et al., 2006; Saeed et al., 2009; Abbas et al.,
2013) by regular methodologies. The synthesized cholesterol
derivatives were evaluated for their antimicrobial studies
(Kakati et al., 2013). The pathogens have been chosen for
antimicrobial screenings were Bacillus subtilis, Staphylococcus
epidermiditis, Proteus vulgaris and Escherichia coli and for
anti-fungal screening were Candida albicans.2. Experimental
2.1. General considerations
Melting points were recorded on sigma melting apparatus
SL111140. IR spectra were recorded in FT-IR Nicolet 6700
thermo scientiﬁc spectrometer using KBr pellet making
method. 1H NMR & 13C NMR spectra were recorded on a
Bruker 300 MHz instrument in CDCl3 with TMS as an inter-
nal standard for proton and carbon spectra. Chemical shift
values are mentioned in d (ppm) and coupling constants are
given in Hz. Mass spectra were recorded on Absciex 3000
LC-MS–MS. The progress of all reactions was monitored by
TLC on 2 · 5 cm pre-coated silica gel 60 F254 plates of thick-
ness of 0.25 mm (Merck). The chromatograms were visualized
under UV 254–366 nm, iodine, and potassium permanganate
strain solution. The elemental analyses were recorded in vario
EL III CHNS element analyser.
2.2. General procedure for the synthesis of (3S,8S,9S,10R,13R,
14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,
7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta
[a]phenanthren-3-yl (tert-butoxycarbonyl)glycinate (2)
TheN-boc glycine (5 g, 28.5 mmol) was dissolved in chloroform
(50 mL) and the solution was cooled to 0 C. To that solution
carbonyldiimidazole (CDI) (4.95 g, 30 mmol) was added under
a nitrogen atmosphere and itwas stirred for 15 min at room tem-
perature. To that reaction mixture, cholesterol (1) (11 g,
28.5 mmol) was added and the reaction mixture was stirred for
24 h at ambient temperature. The completion of the reaction
wasmonitored by thin layer chromatography. The reactionmix-
ture was then diluted with chloroform (250 mL) and washed
with water (2 · 200 mL) and brine solution (200 mL). The
organic layer was dried over anhydrous Na2SO4, ﬁltered and
concentrated. The crude product obtained was subjected to col-
umn chromatography over silica gel (60–120 mesh) by using
ethyl acetate/pet ether (5:95) mixture to obtain 2.
White solid. Yield 73%. mp108–110 C. IR (KBr) cm1:
3380, 2940, 1730, 1680, 1200, 1170. 1H NMR (300 MHz,
CDCl3): d 0.67 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d,J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.90–2.0 (m, 38H),
2.33 (d, J = 7.8 Hz, 2H), 3.88 (d, J = 5.1 Hz, 2H), 4.62–4.75
(m, 1H), 5.03 (s, 1H carbamate NH), 5.36–5.38 (m, 1H). 13C
NMR (75 MHz, CDCl3): 169.82, 155.85, 139.58, 123.06, 80.05,
75.34, 56.90, 56.40, 56.33, 50.27, 42.85, 42.52, 39.94, 39.70,
38.21, 37.12, 36.76, 36.38, 35.94, 32.07, 28.49, 28.36, 28.16,
27.90, 24.44, 24.02, 22.99, 22.93, 22.73, 22.69, 21.22, 19.42,
18.89, 12.02. ESI-LC/MS(M+ + 1)calculated. m/z 544.8.
Found 544.7. Anal.Calcd. for: C34H57NO4: C, 75.09; H, 10.56;
N, 2.58%. Found: C, 75.12; H, 10.53; N, 2.57%.
2.3. General procedure for synthesis of compounds 3, 4l, 4r
The compound 2 (5 g, 9.2 mmol) was dissolved in dichloro-
methane (DCM) (50 mL). To that solution triﬂuoroacetic acid
(TFA) (7.0 mL, 0 92 mmol) was added and stirred for 30 min.
Then the reaction mixture was concentrated, dried and washed
with diethyl ether (25 ml) to obtain 3.
2.3.1. 2-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-
((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-
oxoethan-1-aminium 2,2,2-triﬂuoroacetate (3)
White solid. Yield 92%. mp183–184 C. IR (KBr) cm1: 3090,
2940, 1750, 1680, 1270, 1180. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.03 (26H,
cholesterol), 2.33 (d, J = 7.8 Hz, 2H), 3.74 (s, 2H), 4.62–4.73
(m, 1H), 5.36–5.38 (m, 1H). 13C NMR (75 MHz, DMSO-
D6): d 166.90, 139.09, 122.41, 75.14, 56.14, 55.66, 49.45,
41.85, 40.36, 39.53, 39.29, 37.42, 36.33, 36.04, 35.68, 35.16,
31.35, 27.71, 27.33, 27.12, 23.80, 23.22, 22.55, 22.30, 20.53,
18.85, 18.50, 11.60. ESI-LC/MS(M+ + 1)calculated. m/z
444.7. Found 444.6. Anal.Calcd. for: C31H50F3NO4: C,
66.76; H, 9.04; N, 2.51%. Found: C, 66.73; H, 9.05; N, 2.53%.
2.3.2. 2-((2-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,
17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-
oxoethyl)amino)-2-oxoethan-1-aminium 2,2,2-triﬂuoroacetate
(4l)
White solid. Yield 91%. mp131–132 C. IR (KBr) cm1: 3080,
2930, 1740, 1670, 1260, 1180. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
660 R. Sribalan et al.3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–1.99 (m, 26H,
cholesterol), 2.31 (d, J = 7.8 Hz, 2H), 3.87–3.97 (m, 4H), 4.56–
4.66 (m, 1H), 5.36–5.38 (m, 1H), 8.15 (s, 1H, amide NH). 13C
NMR (75 MHz, CDCl3): d 169.27, 139.39, 122.83, 75.54,
56.78, 56.48, 50.05, 42.40, 41.56, 40.97, 39.87, 39.56, 37.88,
37.84, 36.94, 36.56, 36.33, 35.93, 31.93, 28.30, 28.01, 27.55,
24.35, 24.14, 22.78, 22.56, 21.13, 19.26, 18.79, 11.90. ESI-
LC/MS(M+ + 1)calculated. m/z 501.7. Found 501.5.
Anal.Calcd. for: C33H53F3N2O5: C, 64.47; H, 8.69; N,
4.56%. Found: C, 64.43; H, 8.72; N, 4.59%.
2.3.3. 2-(((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-
((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)
carbonyl)oxy)ethan-1-aminium 2,2,2-triﬂuoroacetate (4r)
White solid. Yield 90%. mp167–169 C. IR (KBr) cm1: 3090,
2930, 1750, 1670, 1270, 1260. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 6H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.04 (26H,
cholesterol), 2.35 (d, J = 7.8 Hz, 2H), 3.24 (t, J = 9.9 Hz,
2H), 4.37 (t, J = 9.9 Hz, 2H), 4.42–4.52 (m, 1H), 5.38–5.40
(m, 1H). 13C NMR (75 MHz, CDCl3): d 153.77, 138.98,
122.83, 78.31, 77.59, 76.73, 63.51, 56.48, 55.98, 49.81, 42.11,
39.84, 37.73, 36.62, 36.30, 35.97, 35.52, 31.65, 27.95, 27.72,
27.40, 24.04, 23.60, 22.56, 22.32, 20.82, 19.01, 18.52, 11.64.
ESI-LC/MS(M++ 1)calculated. m/z 474.7. Found 474.5.
Anal.Calcd. for: C32H52F3NO5: C, 65.39; H, 8.92; N, 2.38%.
Found: C, 65.36; H, 8.96; N, 2.32%.
2.4. General procedure for synthesis of compounds 4a–k, 4p and
4s
Pyrazine 2-carboxylic acid (0.11 g, 0.89 mmol) was dissolved in
tetrahydrofuran (THF) (20 mL) (DMF is used as solvent for
synthesizing compound 4p). To that solution 1-ethyl-3-(3-dime
thylaminopropyl)carbodiimide hydrochloride (EDCI.HCl)
(0.2 g, 1.06 mmol), hydroxy benzotriazole (HOBT) (0.121 g,
0.89 mmol), triethylamine (TEA) (0.3 mL, 1.87 mmol) and
compound 3 (0.5 g, 0.897 mmol) were added. The reaction
mixture was stirred for 24 hours and it was poured into
crushed ice. The white precipitate obtained was ﬁltered which
was subjected to column chromatography over silica gel (60–
120 mesh) by using ethyl acetate/pet ether mixture.
2.4.1. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (pyrazine-2-carbonyl)-
glycinate (4a)
White solid. Yield 70%. mp179–180 C. IR (KBr) cm1: 3360,
1750, 1680, 1270, 1180. 1H NMR (300 MHz, CDCl3): d 0.68 (s,
1H), 0.87 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.90
(d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.01–2.04 (26H, cholesterol),
2.37 (d, J = 7,8 Hz, 2H), 4.25 (d, J = 5.4 Hz, 2H), 4.68–4.78
(m, 1H), 5.38–5.40 (m, 1H), 8.26 (s, 1H amide NH), 8.56–
8.57 (m, 1H), 8.77 (d, J = 2.4 Hz, 1H), 9.40 (d, J = 1.2 Hz,
1H). 13C NMR (75 MHz, CDCl3): d 168.97, 163.33, 147.58,
144.59, 144.28, 142.82, 139.48, 123.14, 75.81, 56.90, 56.39,
50.25, 42.52, 41.70, 39.93, 39.69, 38.20, 37.10, 36.76, 36.38,
35.93, 32.06, 28.35, 28.15, 27.90, 24.44, 24.01, 22.92, 22.68,
21.22, 19.43, 18.89, 12.02. ESI-LC/MS(M++ 1)calculated.m/z 550.8. Found 550.8. Anal.Calcd. for: C34H51N3O3: C,
74.28; H, 9.35; N, 7.64%. Found: C, 74.32; H, 9.30; N, 7.62%.
2.4.2. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (thiophene-2-carbonyl)
glycinate (4b)
White solid. Yield 71%. mp158–159 C. IR (KBr) cm1: 3360,
2950, 1740, 1670, 1210, 1180. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.03 (26H,
cholesterol), 2.36 (d, J = 7.8 Hz, 2H), 4.19 (d, J = 4.8 Hz,
2H), 4.65–4.75 (m, 1H), 5.39–5.41 (m, 1H), 6.57 (s, 1H, amide
NH), 7.07–7.11 (m, 1H), 7.49 (d, J = 4.8 Hz, 1H), 7.56 (d,
J = 3.3 Hz, 1H). 13C NMR (75 MHz, CDCl3): d 169.51,
161.99, 139.47, 138.35, 130.37, 128.69, 127.76, 123.16, 75.82,
56.89, 56.39, 50.24, 42.50, 42.09, 39.92, 39.68, 38.18, 37.08,
36.74, 36.37, 35.93, 32.06, 28.35, 28.14, 27.88, 24.43, 24.01,
22.91, 22.68, 21.20, 19.41, 18.88, 12.01. ESI-
MS(M++ 1)calculated. m/z 554.8. Found 554.8.
Anal.Calcd. for: C34H51NO3S: C, 73.73; H, 9.28; N, 2.53%.
Found: C, 73.78; H, 9.30; N, 2.48%.
2.4.3. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (4-aminobenzoyl)-
glycinate (4c)
White solid. Yield 76%. mp196–197 C. IR (KBr) cm1: 3470,
3370, 2950, 1740, 1630, 1210, 1190. 1H NMR (300 MHz,
CDCl3): d 0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d,
J = 6.6 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H),
1.00–2.04 (26H, cholesterol), 2.36 (d, J = 7.8 Hz, 2H), 4.00
(s, 2H, amine NH2), 4.19 (d, J = 4.8 Hz, 2H), 4.66–4.76 (m,
1H), 5.38–5.41 (m, 1H), 6.54 (s, 1H, amide NH), 6.66 (d,
J = 8.1 Hz, 2H), 7.64 (d, J = 8.1 Hz, 2H). 13C NMR
(75 MHz, CDCl3): d 169.99, 167.31, 150.05, 139.55, 129.02,
123.50, 123.06, 114.25, 75.59, 56.88, 56.37, 50.23, 42.49,
42.17, 39.92, 39.67, 38.19, 37.09, 36.74, 36.36, 35.91, 32.05,
28.34, 28.13, 27.88, 24.42, 24.00, 22.91, 22.67, 21.20, 19.41,
18.87, 12.00. ESI-LC/MS(M+ + 1)calculated. m/z 563.8.
Found 563.6. Anal.Calcd. for: C36H54N2O3: C, 76.82; H,
9.67; N, 4.98% Found: C, 76.79; H, 9.70; N, 2.49%.
2.4.4. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (2-(1H-indol-3-yl)-
acetyl)glycinate (4d)
White solid. Yield 74%. mp192–193 C. IR (KBr) cm1: 3380,
3260, 2940, 1730, 1650, 1290, 1230. 1H NMR (300 MHz,
CDCl3): d 0.67 (s, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.88 (d,
J = 6.6 Hz, 3H), 0.90 (d, J= 6.6 Hz, 3H), 0.99 (s, 3H),
1.00–2.00 (26H, cholesterol), 2.24 (d, J = 7.8 Hz, 2H), 3.79
(s, 2H), 3.94 (d, J = 5.4 Hz, 2H), 4.53–4.64 (m, 1H), 5.32–
5.34 (m, 1H), 6.19 (s, 1H, amide NH), 7.13–7.23 (m, 3H),
7.39 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 8.44 (s,
1H, indole NH). 13C NMR (75 MHz, CDCl3): d 171.93,
169.27, 139.49, 136.65, 127.24, 123.99, 123.02, 122.67, 120.14,
118.84, 111.58, 108.76, 75.46, 56.87, 56.39, 50.22, 42.49,
41.77, 39.91, 39.67, 38.09, 37.05, 36.70, 36.37, 35.91, 33.28,
32.03, 28.33, 28.13, 27.78, 24.41, 24.00, 22.90, 22.67, 21.18,
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601.8. Found 601.6. Anal.Calcd. for: C39H56N2O3: C, 77.96;
H, 9.39; N, 4.66%. Found: C, 77.99; H, 9.43; N, 4.62%.
2.4.5. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl nicotinoylglycinate
(4e)
White solid. Yield 70%. mp139–140 C. IR (KBr) cm1: 3370,
2940, 1750, 1650, 1260, 1210. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H),0.87 (d, J = 6.6 Hz, 3H),
0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.04 (26H, choles-
terol), 2.36 (d, J = 7.8 Hz, 2H), 4.21 (d, J = 4.8 Hz, 2H),
4.67–4.77 (m, 1H), 5.37–5.39 (m, 1H), 7.22 (s, 1H, amide
NH), 7.36–7.40 (m, 1H), 8.14 (d, J = 7.8 Hz, 1H), 8.71 (d,
J = 2.7 Hz, 1H), 9.04 (s, 1H). 13C NMR (75 MHz, CDCl3):
d 169.36, 165.73, 152.53, 148.29, 139.40, 135.26, 129.76,
123.57, 123.18, 75.91, 56.87, 56.38, 50.23, 42.49, 42.18, 39.90,
39.66, 38.16, 37.06, 36.73, 36.35, 35.91, 32.04, 28.33, 28.12,
27.86, 24.41, 24.00, 22.89, 22.66, 21.19, 19.40, 18.87, 11.99.
ESI-LC/MS(M++ 1)calculated. m/z 549.8. Found 549.7.
Anal.Calcd. for: C35H52N2O3: C, 76.60; H, 9.55; N, 5.10%.
Found: C, 76.66; H, 9.51; N, 5.11%.
2.4.6. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl ((E)-3-(3,4,5-
trimethoxyphenyl)acryloyl)glycinate (4f)
White solid. Yield 71%. mp108–109 C. IR (KBr) cm1: 3400,
2940, 1750, 1670, 1240, 1200. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.06 (26H,
cholesterol), 2.35 (d, J = 7.8 Hz, 2H), 3.87 (s, 9H), 4.16 (d,
J = 4.5 Hz, 2H), 4.65–4.75 (m, 1H), 5.34–5.36 (m, 1H), 6.37
(s, 1H, amide NH), 6.45 (d, J = 8.1 Hz, 1H), 6.71 (s, 2H),
7.51 (d, J = 15.6 Hz, 1H). 13C NMR (75 MHz, CDCl3):
169.72, 166.02, 153.58, 141.69, 140.13, 139.46, 130.37, 123.11,
119.53, 105.48, 75.69, 61.00, 56.88, 56.32, 50.24, 42.48, 41.96,
39.90, 39.66, 38.18, 37.07, 36.72, 36.35, 35.91, 32.03, 28.31,
28.11, 27.87, 24.40, 23.98, 22.88, 22.65, 21.19, 19.40, 18.87,
11.98. ESI-LC/MS(M++ 1)calculated. m/z 664.9. Found
664.6. Anal.Calcd. for: C41H61NO6: C, 74.17; H, 9.26; N,
2.11%. Found: C, 74.21; H, 9.25; N, 2.08%.
2.4.7. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (4-hydroxybenzoyl)-
glycinate (4g)
White solid. Yield 72%. mp197–199 C. IR (KBr) cm1: 3570,
3400, 2950, 1790, 1660, 1200, 1180. 1H NMR (300 MHz,
CDCl3): d 0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d,
J = 6.6 Hz, 3H) 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–
2.04 (26H, cholesterol), 2.35 (d, J = 7.8 Hz, 2H), 4.13 (d,
J = 5.1 Hz, 2H), 4.64–4.74 (m, 1H), 5.35–5.37 (m, 1H), 6.86
(d, J = 8.1 Hz, 2H), 7.39 (s, 1H, amide NH), 7.72 (d,
J = 8.4 Hz, 2H), 9.47 (s, 1H, OH). 13C NMR (75 MHz,
CDCl3):d 169.54, 167.30, 160.53, 139.29, 128.96, 124.73,
122.61, 115.22, 74.99, 56.53, 56.02, 49.89, 42.49, 42.18, 39.90,
39.66 , 37.88, 36.76, 36.40, 36.01, 35.55, 31.70, 27.99, 27.76,
27.55, 24.08, 23.63, 22.59, 22.36, 20.85, 19.08, 18.55, 11.68.
ESI-LC/MS(M++ 1)calculated. m/z 564.4. Found 565.5.Anal.Calcd. for: C36H53NO4: C, 76.69; H, 9.47; N, 2.48%.
Found: C, 77.71; H, 9.45; N, 2.48%.
2.4.8. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl ((1R,3R)-adaman-
tane-1-carbonyl)glycinate (4h)
White solid. Yield 72%. mp177–178 C. IR (KBr) cm1: 3350,
2930, 1750, 1670, 1250, 1200. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6, 3H), 0.87 (d, J = 6.6 Hz, 3H),
0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.05 (42H), 2.34
(d, J = 7.8 Hz, 2H), 3.99 (d, J = 4.8 Hz, 2H), 4.62–4.72 (m,
1H), 5.37–5.39 (m, 1H), 6.18 (s, 1H, amide NH). 13C NMR
(75 MHz, CDCl3): d 178.19, 169.90, 139.45, 123.07, 75.52,
60.50, 56.81, 56.27, 50.13, 42.43, 41.63, 40.73, 39.84, 39.64,
39.26, 38.13, 37.02, 36.69, 36.62, 36.31, 35.90, 32.02, 31.96,
28.34, 28.21, 28.13, 27.82, 24.40, 23.95, 22.93, 22.68, 21.15,
19.40, 18.84, 14.31, 11.97. ESI-LC/MS(M++ 1)calculated.
m/z 606.9. Found 606.8. Anal.Calcd. for: C40H63NO3: C,
79.29;H, 10.48;N, 2.31%. Found: C, 79.31;H, 10.48;N, 2.28%.
2.4.9. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (2,4-dihydroxy-
benzoyl)glycinate (4i)
White solid. Yield 71%. mp232–233 C. IR (KBr) cm1: 3400,
3350, 2940, 1730, 1640, 1220, 1170. 1H NMR (300 MHz,
CDCl3): d 0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d,
J = 6.6 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H),
1.00–2.03 (26H, cholesterol), 2.35 (d, J = 7.8 Hz, 2H), 4.10
(d, J = 5.4 Hz, 2H), 4.62–4.73 (m, 1H), 5.36–5.38 (m, 1H),
6.37 (d, J = 2.4 Hz, 2H), 7.51 (d, J = 8.7 Hz, 1H), 7.80 (s,
1H, amide NH), 9.58 (bs, 1H, OH), 12.32 (bs, 1H, OH). 13C
NMR (75 MHz, CDCl3): d 170.00, 169.25, 163.07, 162.64,
139.28, 128.21, 122.68, 107.53, 106.53, 103.51, 75.15, 56.56,
56.05, 49.91, 42.18, 41.36, 39.90, 39.66, 37.90, 36.79, 36.44,
36.04, 35.58, 31.73, 28.03, 27.80, 27.58, 24.11, 23.67, 22.63,
22.39, 20.89, 19.12, 18.59, 11.71. ESI-
LC/MS(M++ 1)calculated. m/z 580.8. Found 580.7.
Anal.Calcd. for: C36H53NO5: C, 74.57; H, 9.21; N, 2.42%.
Found: C, 74.55; H, 9.18; N, 2.45%.
2.4.10. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (2-(4-hydrox-
yphenyl)acetyl)glycinate (4j)
White solid. Yield 70%. mp146–147 C. IR (KBr) cm1: 3400,
3300, 2950, 1750, 1650, 1220, 1190. 1H NMR (300 MHz,
CDCl3): d 0.67 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d,
J = 6.6 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H),
1.00–2.03 (26H, cholesterol), 2.30 (d, J = 7.8 Hz, 2H), 3.55
(s, 2H), 3.98 (d, J = 5.1 Hz, 2H), 4.58–4.68 (m, 1H), 5.34–
5.36 (m, 1H), 6.15 (s, 1H, amide NH), 6.75 (d, J = 8.4 Hz,
2H), 7.09 (d, J = 8.4 Hz, 2H). 13C NMR (75 MHz, CDCl3):
d 172.73, 169.40, 155.87, 139.33, 130.86, 125.58, 123.19,
116.19, 75.84, 56.81, 56.29, 50.12, 42.56, 42.45, 41.88, 39.85,
39.65, 38.07, 37.00, 36.68, 36.33, 35.93, 32.02, 31.96, 28.36,
28.15, 27.78, 24.41, 23.99, 22.95, 22.70, 21.16, 19.40, 18.85,
11.99. ESI-LC/MS(M++ 1)calculated. m/z 578.8. Found
578.7. Anal.Calcd. for: C37H55NO4: C, 76.91; H, 9.59; N,
2.42%. Found: C, 76.90; H, 9.60; N, 2.41%.
662 R. Sribalan et al.2.4.11. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (tert-butoxycar-
bonyl)glycylglycinate (4k)
White solid. Yield 71%. mp120–121 C. IR (KBr) cm1: 3330,
2940, 1750, 1680, 1250, 1200. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.06 (35H),
2.33 (d, J = 7.8 Hz, 2H), 3.86 (d, J = 5.4 Hz, 2H), 4.03 (d,
J = 5.4 Hz, 2H), 4.61–4.72 (m, 1H), 5.36–5.38 (m, 1H), 6.15
(s, 1H, carbamate NH), 6.85 (s, 1H, amide NH). 13C NMR
(75 MHz, CDCl3): d 169.94, 169.30, 156.17, 139.39, 123.10,
80.41, 75.60, 56.80, 56.27, 50.12, 42.42, 41.55, 39.83, 39.62,
38.09, 37.00, 36.66, 36.30, 35.90, 32.00, 31.94, 28.42, 28.33,
28.11, 27.78, 24.38, 23.96, 22.92, 22.67, 21.14, 19.39, 18.83,
11.96. ESI-LC/MS(M++ OAc) calculated. m/z 659.8.
Found 659.8. Anal.Calcd. for: C36H60N2O5: C, 71.96; H,
10.06; N, 4.66%. Found: C, 71.94; H, 10.05; N, 4.67%.
2.4.12. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl 2-(1H-tetrazol-1-yl)-
acetate (4p)
White solid. Yield 42%. mp195–196 C. IR (KBr) cm1: 2930,
1750, 1240, 1170. 1H NMR (300 MHz, CDCl3): d 0.68 (s, 3H),
0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.90 (d,
J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.04 (26H, cholesterol),
2.35 (d, J = 7.8 Hz, 2H), 4.70–4.80 (m, 1H), 5.23 (s, 2H),
5.38–5.40 (m, 1H), 8.81 (s, 1H). 13C NMR (75 MHz, CDCl3):
d 169.82, 155.85, 139.58, 123.06, 75.34, 56.90, 56.40, 50.27,
42.85, 42.52, 39.94, 39.70, 38.21, 37.12, 36.76, 36.38, 35.94,
32.07, 28.49, 28.36, 28.16, 27.90, 24.44, 24.02, 22.93, 22.69,
21.22, 19.42, 18.89, 12.02. ESI-LC/MS(M++ 1)calculated.
m/z 497.7. Found 497.7. Anal.Calcd. for: C30H48N4O2: C,
72.54;H, 9.74;N, 11.28%. Found: C, 72.54;H, 9.75; N, 11.27%.
2.4.13. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (2-(nicotinamido)-
ethyl) carbonate (4s)
White solid. Yield 70%. mp146–147 C. IR (KBr) cm1: 3380,
2950, 1740, 1650, 1260, 1240. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.04 (26H,
cholesterol), 2.38 (d, J = 7.8 Hz, 2H), 3.79 (q, 2H), 4.35 (t,
J = 9.6 Hz, 2H), 4.43–4.54 (m, 1H), 5.37–5.39 (m, 1H), 7.00
(s, 1H, amide NH), 7.40 (m, 1H), 8.14 (d, J = 8.1 Hz, 1H),
8.73 (d, J = 4.8 Hz, 1H), 9.01 (s, 1H). 13C NMR (75 MHz,
CDCl3): d 165.84, 154.78, 152.43, 148.11, 139.19, 135.36,
130.00, 123.64, 123.31, 78.59, 66.42, 56.79, 56.25, 50.10,
42.43, 39.82, 39.68, 39.63, 38.10, 36.92, 36.64, 36.30, 35.90,
31.94, 28.33, 28.12, 27.78, 24.39, 23.94, 22.93, 22.68, 21.16,
19.36, 18.83, 11.97. ESI-LC/MS(M+ + 1)calculated. m/z
579.8. Found 579.7. Anal.Calcd. for: C36H54N2O4C, 74.70;
H, 9.40; N, 4.84%. Found: C, 74.71; H, 9.41; N, 4.85%.2.5. General procedure for synthesis of compounds 4n and 4o
The compound 3 (0.5 g, 0.897 mmol) was dissolved in dichloro-
methane (DCM) (20 mL). To that solution triethylamine (TEA)(0.31 mL, 2.24 mmol) and isocyanate (0.1 g, 0.897 mmol) were
added at 0 C. The reaction mixture was stirred for 30 min at
room temperature. The product was extracted with dichloro-
methane (100 mL) andwashedwithwater (2 · 75 mL) and brine
(75 mL) solution. The organic layer was separated, dried over
anhydrous Na2SO4, ﬁltered and concentrated. The crude pro-
duct obtained was puriﬁed by column chromatography over sil-
ica gel using ethyl acetate/pet ether mixture.
2.5.1. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (phenylcarbamoyl)-
glycinate (4n)
White solid. Yield 70%. mp177–178 C. IR (KBr) cm1: 3330,
2940, 1750, 1680, 1250, 1200. 1H NMR (300 MHz, CDCl3): d
0.67 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.03 (26H,
cholesterol), 2.30 (d, J = 7.8 Hz, 2H), 3.99 (d, J = 4.8 Hz,
2H), 4.58–4.68 (m, 1H), 5.32-5.34 (m, 1H), 5.99 (s, 1H, urea
NH), 6.98–7.03 (m, 1H), 7.19–7.33 (m, 4H), 7.55 (s, 1H, urea
NH). 13C NMR (75 MHz, CDCl3): d 170.88, 156.24, 139.45,
138.65, 129.25, 129.17, 123.72, 123.07, 120.91, 120.58, 75.57,
56.85, 56.34, 50.14, 42.46, 39.88, 39.65, 38.12, 37.03, 36.68,
36.34, 35.95, 32.03, 31.96, 28.37, 28.14, 27.81, 24.41, 24.03,
22.95, 22.70, 21.16, 19.41, 18.86, 11.99. ESI-
LC/MS(M+ + 1)calculated. m/z 563.8. Found 563.5.
Anal.Calcd. for: C36H54N2O3:C, 76.82; H, 9.67; N, 4.98%.
Found: C, 76.81; H, 9.67; N, 4.99%.
2.5.2. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (cyclohexylcar-
bamothioyl)glycinate (4o)
White solid. Yield.71%. mp141–142 C. IR (KBr) cm1: 3330,
2930, 1740, 1550, 1260, 1210. 1H NMR (300 MHz, CDCl3): d
0.68 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.04 (36H,
cholesterol), 2.35 (d, J = 7.8 Hz, 2H), 3.63–3.73 (m, 1H),
4.38 (d, J = 4.5 Hz, 1H), 4.63–4.73 (m, 1H), 5.37–5.39 (m,
1H), 6.33–6.39 (m, 2H, thiourea NH). 13C NMR (75 MHz,
CDCl3): d 181.03, 170.06, 139.43, 123.17, 75.94, 56.88, 56.37,
52.91, 50.23, 46.93, 42.49, 39.90, 39.66, 38.15, 37.08, 36.74,
36.35, 35.92, 32.79, 32.05, 28.34, 28.13, 27.85, 25.53, 24.78,
24.41, 23.99, 22.92, 22.67, 21.19, 19.41, 18.86, 12.00. ESI-
LC/MS(M+ + 1)calculated. m/z 585.9. Found 585.6.
Anal.Calcd. for: C36H60N2O2S: C, 73.92; H, 10.34; N,
4.79%. Found: C, 73.91; H, 10.33; N, 4.79%.
2.6. General procedure for synthesis of compound 4m and 4t
The compound 3 (0.5 g, 0.897 mmol) was dissolved in dichlor-
omethane (DCM) (5 mL). To that solution triethylamine
(TEA) (0.32 mL, 2.25 mmol) and p-toluene sulphonyl chloride
(PTS-Cl) (0.17 g, 0.897 mmol) were added at 0 C. The reac-
tion mixture was stirred for 30 min at room temperature.
Then the reaction mixture was diluted with dichloromethane,
(100 mL) and washed with water (2 · 75 mL) and brine
(75 mL) solution. The organic layer was separated, dried over
anhydrous Na2SO4, ﬁltered and concentrated. The crude pro-
duct obtained was puriﬁed by column chromatography over
silica gel using ethyl acetate/pet ether mixture.
Scheme 1 Synthetic route for glycinate derivatives of cholesterol (4a–o).
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6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl tosylglycinate (4m)
White solid. Yield: 80%. mp130–131 C. IR (KBr) cm1: 3320,
2940, 1740, 1710, 1240, 1210. 1H NMR (300 MHz, CDCl3): d
0.67 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz,
3H), 0.90 (d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.02 (26H,
cholesterol), 2.16 (d, J = 7.8 Hz, 2H), 2.32 (s, 3H), 3.75 (d,
J = 4.8 Hz, 2H), 4.46–4.56 (m, 1H), 5.17 (s, 1H), 5.31–5.33
(m, 1H), 7.30 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H).
13C NMR (75 MHz, CDCl3): d 168.31, 143.87, 139.19,
136.37, 129.87, 127.44, 123.20, 75.96, 56.78, 56.26, 50.09,
44.51, 42.42, 39.81, 39.63, 37.93, 36.93, 36.62, 36.30, 35.90,31.93, 28.33, 28.13, 27.62, 24.39, 23.96, 22.94, 22.69, 21.67,
21.13, 19.36, 18.84, 11.97. ESI-LC/MS(M+  1)calculated.
m/z 596.8. Found 596.5. Anal.Calcd. for: C36H55NO4S: C,
72.32; H, 9.27; N, 2.34%. Found: C, 72.31; H, 9.25; N, 2.33%.
2.6.2. (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-
6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradec-
ahydro-1H-cyclopenta[a]phenanthren-3-yl (2-((4-methylphenyl)-
sulfonamido)ethyl) carbonate (4t)
White solid. Yield: 78%. mp148–149 C. IR (KBr) cm1: 3270,
2940, 1740, 1650, 1450, 1270, 1200. 1H NMR (300 MHz,
CDCl3): d 0.68 (s, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.88 (d,
J = 6.6 Hz, 3H), 0.90 (d, J = 6.5 Hz, 3H), 0.99 (s, 3H),
664 R. Sribalan et al.1.00–2.00 (26H, cholesterol), 2.36 (d, J = 7.8 Hz, 2H), 2.43 (s,
3H), 3.22–3.26 (q, 2H), 4.14 (t, J = 10.2 Hz, 2H), 4.39–4.49
(m, 1H), 5.01 (s, 1H), 5.38–5.40 (m, 1H), 7.31 (d,
J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H). 13C NMR
(75 MHz, CDCl3):d 154.22, 143.75, 139.23, 136.97, 129.93,
127.19, 123.26, 78.50, 77.58, 77.16, 76.74, 66.17, 56.79, 56.25,
50.10, 42.43, 42.24, 39.83, 39.63, 38.06, 36.92, 36.63, 36.30,
35.90, 31.95, 28.34, 28.12, 27.74, 24.39, 23.95, 22.94, 22.68,
21.65, 21.15, 19.37, 18.84, 11.97. ESI-
LC/MS(M+  1)calculated. m/z 626.9. Found 626.6.
Anal.Calcd. for: C37H57NO5S: C, 70.77; H, 9.15; N, 2.23%.
Found: C, 70.76; H, 9.18; N, 2.20%.
2.7. General procedure for preparation of compound 4q
The cholesterol 1 (2 g, 5.1 mmol) was dissolved in chloroform
(CHCl3) (20 mL). To that solution carbonyldiimidazole (CDI)
(0.839 g, 5.1 mmol) was added and reﬂuxed for an hour. Then
N-boc ethanolamine (0.834 g, 5.1 mmol) was added and it was
further reﬂuxed for 3 h. The completion of the reaction was
monitored by thin layer chromatography. The product was
extracted with chloroform (200 mL) and washed with water
(2 · 150 mL) and brine (150 mL) solution. The organic layer
was separated and dried over anhydrous Na2SO4, ﬁltered
and concentrated. The product was puriﬁed by column chro-
matography over silica gel using ethyl acetate/pet ether (1:9)
mixture to obtain 4q.HO
H
H
H
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O
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Scheme 2 Synthetic route for carbona2.7.1. Tert-butyl (2-(((((3S,8S,9S,10R,13R,14S,17R)-10,13-
dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,
14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)
oxy)carbonyl)oxy)ethyl)carbamate (4q)
White solid. Yield. 64%. mp79–80 C. IR (KBr) cm1: 3370,
2960, 1750, 1690, 1260, 1170. 1H NMR (300 MHz, CDCl3):
d 0.68 (s, 3H), 0.86 (d, J= 6.6 Hz, 3H), 0.87 (d, J= 6.6 Hz,
3H), 0.90 (d, J= 6.6 Hz, 3H), 0.99 (s, 3H), 1.00–2.03 (35H),
2.40 (d, J= 7.8 Hz, 2H), 3.40–3.43 (q, 2H), 4.18 (t,
J= 9.9 Hz, 2H), 4.43–4.53 (m, 1H), 4.89 (s, 1H, carbamate
NH), 5.49–5.51 (m, 1H). 13C NMR (75 MHz, CDCl3): d
155.84, 154.52, 139.42, 123.21, 79.76, 78.27, 77.58, 77.16,
76.74, 66.99, 56.86, 56.29, 50.15, 42.48, 39.87, 39.66, 38.16,
37.00, 36.69, 36.34, 35.93, 32.04, 28.50, 28.36, 28.15, 27.84,
24.42, 23.97, 22.96, 22.70, 21.19, 19.40, 18.86, 12.00. ESI-
LC/MS(M+ + 1)calculated. m/z 591.8. Found 591.7.
Anal.Calcd. for: C35H59NO5: C, 73.26; H, 10.36; N, 2.44%.
Found: C, 73.29; H, 10.35; N, 2.42%.
2.8. Antimicrobial activity
The bacterial strains used for the examinations were B. subtilis
(ATCC 10876), S. epidermiditis (ATCC 25923), P. vulgaris
(ATCC 27836) and E. coli (ATCC 25922), and fungal strain
is C. albicans (ATCC 66027) obtained from either American
type culture collection or purchased from Himedia, Mumbai.O
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Table 1 List of synthesised cholesterol derivatives 4a–t.
Entry Structure of the compound Entry Structure of the compound
4a 4k
4b 4l
4c 4m
4d 4n
4e 4o
4f 4p
4g 4q
4h 4r
4i 4s
4j 4t
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Table 2 Antimicrobial activity of cholesterol derivatives (4a–t).
S no. Compound Zone of inhibition (mm)
Escherchia coli Proteus vulgaris Staphylococcus epidermiditis Bacillus subtilis Candida albicans
1 4a 6.2 ± 0.2 5.0 ± 0.2 – – 12.2 ± 0.3
2 4b 5.1 ± 0.3 4.2 ± 0.3 – – 9.1 ± 0.2
3 4c – – – – –
4 4d 4.9 ± 0.2 15.1 ± 0.3 – – 5.8 ± 0.5
5 4e 8.3 ± 0.1 14.4 ± 0.2 – – 6.8 ± 0.4
6 4f – 14.5 ± 0.2 – – –
7 4g – – – – –
8 4h – 11.2 ± 0.1 – – 8.0 ± 0.4
9 4i – – – – –
10 4j – – – – –
11 4k – 8.9 ± 0.5 – – 9.1 ± 0.5
12 4l 9.4 ± 0.4 14.1 ± 0.2 – – 8.0 ± 0.3
13 4m 6.8 ± 0.4 13.8 ± 0.4 – – 11.2 ± 0.2
14 4n 14.1 ± 0.3 16.2 ± 0.2 – – –
15 4o 7.3 ± 0.2 – – – 7.9 ± 0.3
16 4p – – – – –
17 4q – 9.3 ± 0.5 – – 11.2 ± 0.2
18 4r 9.3 ± 0.3 18.1 ± 0.2 – – 9.4 ± 0.3
19 4s 8.1 ± 0.2 11.2 ± 0.3 – – 14.1 ± 0.2
20 4t – – – – –
21 Control – – – – –
22 Amikacin 17.0 ± 0.1 20.1 ± 0.2 18.2 ± 0.1 19.8 ± 0.3 –
23 Ketoconazole – – – – 17.0 ± 0.2
1. (–) no inhibition.
2. Control: DMSO.
666 R. Sribalan et al.Amikacin and ketoconazole are used as standard for antibac-
terial and antifungal substances respectively. The analogous
conditions, dimethyl sulfoxide (DMSO) was used as negative
control. The biological studies were carried out in the Bose
clinical laboratory, Madurai, India.
The test organisms were overnight cultured on agar slants
and incubated at (37 ± 0.5 C and 24–48 h) for bacteria and
fungi (37 ± 0.5 C and 36 h) respectively to get the freshly pre-
pared cultures. The cholesterol derivatives were evaluated for
antimicrobial activity by the well diffusion method. Muller
Hinton Agar (MHA) media were used for bacteria and
Potato dextrose agar (PDA) media were used for fungal strains
respectively. After sterilization, the medium was inoculated
with freshly cultured bacterial strains under sterile condition
that is under Laminar Flow. The inoculation was carried out
when the temperature of the medium reached until 40–50 C.
The medium inoculated with test microorganisms was trans-
ferred into the plates of 90 mm size under sterile conditions.
The medium was allowed to solidify and the wells (4/plate)
of 6 mm diameter and 50 lL volume were bored on it by using
sterile cork borer. The solution of test compounds 1000 lg/mL
was prepared in DMSO and the wells bored on the medium
were each ﬁlled (50 lg) with test compound using micropipette
(20–200 lL). Four wells were bored on the plates and each
ﬁlled with same compound and two plates for each test com-
pound were taken and the experiments were repeated twice.
The discs of amikacin and ketoconazole were also incorpo-
rated into the medium for comparison. The plates containing
test organism and test material in contact were incubated at
37 ± 0.5 C for 24 h. Identical procedure was employed for
antifungal activity, however the culture strains of fungi and
the plates were incubated at 37 ± 0.2 C for 36–72 h.Inhibition of growth of test organisms (bacterial and fungal)
in the presence of the test material and the standard was mea-
sured with the help of standard scale and the mean values of
inhibition zones were reported in Table 2.3. Results and discussions
3.1. Chemistry
In the present work, we synthesized a new series of glycinate
derivatives of cholesterol 4a–o, tetrazolyl acetate of cholesterol
4p and carbonate derivatives of cholesterol 4q–r. The ﬁrst step
in Scheme 1 was the coupling of commercially available choles-
terol with N-boc glycine in the presence of carbonyldiimida-
zole (yield 73%). The deprotection of N-boc cholesteryl
glycinate afforded the compound 3 in 92% yield. Further the
compound 3 was converted into carboxamide (4a–l) by the
reaction of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide,
hydroxy benzotriazole and corresponding acids (yield 70–
76%). Again, the compound 3 was converted into sulphona-
mide (4m) derivative by the reaction of p-toluene sulphonyl
chloride in the presence of triethylamine (yield 80%). The phe-
nyl urea and cyclohexyl thiourea derivatives of cholesterol (4n
and 4o) were synthesized with excellent yield by using phenyl
isocyanate and cyclohexyl isothiocyanate in the presence of tri-
ethylamine. The compound 4p built by the coupling of tetra-
zole acetic acid with cholesterol was followed by the same
procedure which was used for compound (4a–l) (yield 65%).
Scheme 2 was the outline for synthesis of carbonate (4q–r)
derivatives of cholesterol. The compound 4q was synthesized
by the carbonylation reaction between cholesterol and N-boc
Evaluation of antimicrobial activity of glycinate and carbonate derivatives of cholesterol 667ethanolamine (yield 64%). The deprotection of compound 4q
gave the product 4r in 92% yield. The compound 4r was fur-
ther subjected to amide and sulphonamide by following the
same protocol as described for 4s and 4t. All the synthesized
compounds were characterized by 1H NMR, 13C NMR,
Mass and IR spectroscopies. The appearance of NH protons
in 1H NMR, the appearance of carbonyl peak in 13C NMR
and the observed stretching frequency of 1700 cm1 in IR
spectra indicate the formation of either amides or urea deriva-
tives. In addition 2D NMR spectra (1H–1H, 13C–1H and
HMBC correlation spectrum) were recorded for the com-
pounds 4d and 4t. For the compound 4d, the correlation of
7.39 & 7.20, 8.44 & 7.14 and 6.12 & 3.93 in 1H–1H Cosy,
and the correlation of 7.59 & 118.83, 7.39 & 111.57, 7.20 &
122.64, 3.94 & 42.49 in 13C–1H cosy indicate the presence
of indolyl acetate and glycinyl unit. Similarly the correlation
of 3.94 & 171.93, 6.19 & 171.93, 3.78 & 169.72, 8.44 &
123.99, 8.44 & 136.65, 7.59 & 108.75 in HMBC also indicates
the presence of indolyl and glycinyl unit. In the compound 4t,
the correlation of 7.73 & 7.30 in 1H–1H cosy and the corre-
lation of 7.74 & 127.19, 7.74 & 129.92, 2.42 & 50.09 in
13C–1H cosy indicate the presence of tosyl ring. The correla-
tion of 4.43 & 154.22, 5.00 & 154.22 in HMBC indicates that
the carbonate was attached with cholesterol. The correlation
of 2.42 & 136.96, 2.42 & 127.19 indicates the presence of
tosyl group. The list of synthesized compounds was summa-
rized in Table 1.3.2. Biology
3.2.1. Antimicrobial activity
A series of 20 compounds were tested against microorganism
such as B. subtilis, S. epidermiditis, P. vulgaris and E. coli
and fungi C. albicans. Among the synthesized compounds,
4a, 4b, 4d, 4e, 4l, 4m, 4n, 4o, 4r and 4s were exhibited activity
against E. coli and 4a, 4b, 4d, 4e, 4f, 4h, 4k, 4l, 4m, 4n, 4q, 4r
and 4s were showed moderate activity against P. vulgaris. The
compounds 4a, 4b, 4d, 4e, 4h, 4k, 4l, 4m, 4o, 4q, 4r and 4s were
exerted activity against fungi. None of these compounds were
active against gram-positive bacteria such as B. subtilis and S.
epidermiditis. Furthermore, the compounds 4a, 4b, 4d, 4e, 4l,
4m, 4r, 4s and 4t were active against both gram-negative bac-
teria and fungi. From the data, it was clear that the com-
pounds 4a, 4b, 4d, 4e and 4s possess heterocyclic unit is
responsible for antimicrobial activities. On the other hand,
compounds 4m and 4t have sulphonyl group might provoke
antimicrobial activity, because it is a well known fact that
many drugs for antibiotics are of sulpha drugs. The zones of
inhibition (in mm) of synthesized compounds were summa-
rized in Table 2.4. Conclusion
In summary, a new series of 20 glycinates and carbonates
derivatives of cholesterol were synthesized and evaluated their
antimicrobial activity. Among all the compounds, 4a, 4b, 4d,
4e, 4l, 4m, 4r, 4s and 4t were active against both gram-
negative bacteria and fungi. With these achievements, we are
trying to improve the biological activities further with the
cholesterol derivatives.Acknowledgement
The grateful thanks to DST and UGC, New Delhi, for ﬁnan-
cial support and DST-IRHPA programme for providing high
resolution NMR facility.
References
Abbas, S.Y., El-Sharief, M.A., Basyouni, W.M., Fakhr, I.M., El-
Gammal, E.W., 2013. Thiourea derivatives incorporating a hip-
puric acid moiety: synthesis and evaluation of antibacterial and
antifungal activities. Eur. J. Med. Chem. 64, 111–120.
Aslan, H.G., Ozcan, S., Karacan, N., 2012. The antibacterial activity
of some sulfonamides and sulfonyl hydrazones, and 2D-QSAR
study of a series of sulfonyl hydrazones. Spectrochim. Acta Part A:
Mol. Biomol. Spectrosc. 98, 329–336.
Banday, M.R., Farshori, N.N., Ahmad, A., Khan, A.U., Rauf, A.,
2010. Synthesis and characterization of novel fatty acid analogs of
cholesterol: in vitro antimicrobial activity. Eur. J. Med. Chem. 45,
1459–1464.
Basanagouda, M., Shivashankar, K., Kulkarni, M.V., Rasal, V.P.,
Patel, H., Mutha, S.S., 2010. Synthesis and antimicrobial studies on
novel sulfonamides containing 4-azidomethyl coumarin. Eur. J.
Med. Chem. 45, 1151–1157.
Bildziukevich, U., Ra´rova´, L., Saman, D., Havlicek, L., Drasar, P.,
Wimmer, Z., 2013. Amides derived from heteroaromatic amines
and selected steryl hemiesters. Steroids 78, 1347–1352.
Brunel, J.M., Loncle, C., Vidal, N., Dherbomez, M., Letourneux, Y.,
2005. Synthesis and antifungal activity of oxygenated cholesterol
derivatives. Steroids 70, 907–912.
Carpino, L.A., Mansour, E.M.E., Knapczyk, J., 1983. Piperazino-
functionalized silica gel as a deblocking-scavenging agent for the 9-
ﬂuorenylmethyloxycarbonyl amino-protecting group. J. Org.
Chem. 48, 666–669.
Chambhare, R., 2003. Synthesis and preliminary evaluation of some
N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]-
carboxamide and 3-substituted-5-(2-furanyl)-2-methyl-3H-
thieno[2,3-d]pyrimidin-4-ones as antimicrobial agents. Eur. J.
Med. Chem. 38, 89–100.
De Logu, A., Palchykovska, L.H., Kostina, V.H., Sanna, A., Meleddu,
R., Chisu, L., 2009. Novel N-aryl- and N-heteryl phenazine-1-
carboxamides as potential agents for the treatment of infections
sustained by drug-resistant and multidrug-resistantMycobacterium
tuberculosis. Int. J. Antimicrob. Agents 33, 223–229.
Faidallah, H.M., Khan, K.A., Asiri, A.M., 2011. Synthesis and
biological evaluation of new 3,5-di(triﬂuoromethyl)-1,2,4-triazole-
sulfonylurea and thiourea derivatives as antidiabetic and antimi-
crobial agents. J. Fluorine Chem. 132, 870–877.
Fernandez-Herrera, M.A., Lopez-Munoz, H., Hernandez-Vazquez,
J.M., Sanchez-Sanchez, L., Escobar-Sanchez, M.L., Pinto, B.M.,
2012. Synthesis and selective anticancer activity of steroidal
glycoconjugates. Eur. J. Med. Chem. 54, 721–727.
Gogoi, S., Shekarrao, K., Duarah, A., Bora, T.C., Gogoi, S., Boruah,
R.C., 2012. A microwave promoted solvent-free approach to
steroidal quinolines and their in vitro evaluation for antimicrobial
activities. Steroids 77, 1438–1445.
Ha, W., Wu, H., Wang, X.L., Peng, S.L., Ding, L.S., Zhang, S., 2011.
Self-aggregates of cholesterol-modiﬁed carboxymethyl konjac glu-
comannan conjugate: preparation, characterization, and prelimi-
nary assessment as a carrier of etoposide. Carbohydr. Polym. 86,
513–519.
Hearn, M.J., Chen, M.F., Cynamon, M.H., Wang’ondu, R., Webster,
E.R., 2006. Preparation and properties of new antitubercular
thioureas and thiosemicarbazides. J. Sulfur Chem. 27, 149–164.
Kakati, D., Sarma, R.K., Saikia, R., Barua, N.C., Sarma, J.C., 2013.
Rapid microwave assisted synthesis and antimicrobial bioevalua-
tion of novel steroidal chalcones. Steroids 78, 321–326.
668 R. Sribalan et al.Kamal, A., Swapna, P., Shetti, R.V., Shaik, A.B., Narasimha Rao,
M.P., Gupta, S., 2013. Synthesis, biological evaluation of new
oxazolidino-sulfonamides as potential antimicrobial agents. Eur. J.
Med. Chem. 62, 661–669.
Keche, A.P., Hatnapure, G.D., Tale, R.H., Rodge, A.H., Birajdar,
S.S., Kamble, V.M., 2012. A novel pyrimidine derivatives with aryl
urea, thiourea and sulfonamide moieties: synthesis, anti-inﬂamma-
tory and antimicrobial evaluation. Bioorg. Med. Chem. Lett. 22,
3445–3448.
Krishnamurthy, S., Gupta, V., Prasad, R., Panwar, S.L., Prasad, R.,
1998. Expression of CDR1, a multidrug resistance gene of Candida
albicans: transcriptional activation by heat shock, drugs and human
steroid hormones. FEMS Microbiol. Lett. 160, 191–197.
Li, Y.G., Fang, Y., Liu, J., Wang, M.Z., 2006. Synthesis and gelation
behavior of cholesteryl glycinate anthraquinone-2-carboxylamide
and cholesteryl glycinate 9,10-dimethyloxyl anthracene-2-carboxy-
lamide. J. Chin. Chem. Soc. 53, 359–366.
Loncle, C., Brunel, J.M., Vidal, N., Dherbomez, M., Letourneux, Y.,
2004. Synthesis and antifungal activity of cholesterol-hydrazone
derivatives. Eur. J. Med. Chem. 39, 1067–1071.
Lone, I.H., Khan, K.Z., Fozdar, B.I., Hussain, F., 2013. Synthesis
antimicrobial and antioxidant studies of new oximes of steroidal
chalcones. Steroids 78, 945–950.
Luo, Z., Williams, J., Read, R.W., Curran, D.P., 2001. Fluorous Boc
(FBoc) carbamates: new amine protecting groups for use in
ﬂuorous synthesis. J. Org. Chem. 66, 4261–4266.
Maitraie, D., Hung, C.F., Tu, H.Y., Liou, Y.T., Wei, B.L., Yang, S.C.,
2009. Synthesis, anti-inﬂammatory, and antioxidant activities of
18beta-glycyrrhetinic acid derivatives as chemical mediators and
xanthine oxidase inhibitors. Bioorg. Med. Chem. 17, 2785–2792.
Mayer, C.D., Bracher, F., 2011. Cytotoxic ring a-modiﬁed steroid
analogues derived from Grundmann’s ketone. Eur. J. Med. Chem.
46, 3227–3236.
Mohamed, N.R., Abdelhalim, M.M., Khadrawy, Y.A., Elmegeed,
G.A., Abdel-Salam, O.M.E., 2012. One-pot three-component
synthesis of novel heterocyclic steroids as a central antioxidant
and anti-inﬂammatory agents. Steroids 77, 1469–1476.
Mooradian, D.A., 1993. Antioxidant properties of steroids. J. Steroid
Biochem. Mol. Biol. 45, 509–511.
Moreno, E., Ancizu, S., Perez-Silanes, S., Torres, E., Aldana, I.,
Monge, A., 2010. Synthesis and antimycobacterial activity of newquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Eur. J.
Med. Chem. 45, 4418–4426.
Ozbek, N., Katircioglu, H., Karacan, N., Baykal, T., 2007. Synthesis,
characterization and antimicrobial activity of new aliphatic sul-
fonamide. Bioorg. Med. Chem. 15, 5105–5109.
Paul, R., Anderson, G.W., 1960. N,N0-carbonyldiimidazole, a new
peptide forming reagent. J. Am. Chem. Soc. 82, 4596–4600.
Prokai-Tatrai, K., Perjesi, P., Rivere-portalatin, N.M., Simpkins,
J.W., Prokai, L., 2008. Mechanistic investigations on the antiox-
idant action of a neuroprotective estrogen derivative. Steroids 73,
280–288.
Rao, P.N., Cessac, J.W., Tinley, T.L., Mooberry, S.L., 2002. Synthesis
and antimitotic activity of novel 2-methoxyestradiol analogs.
Steroids 67, 1079–1089.
Reddy, M.V.R., Mallireddigari, M.R., Pallela, V.R., Cosenza, S.C.,
Billa, V.K., Akula, B., 2013. Design, synthesis, and biological
evaluation of (E)-N-Aryl-2-arylethenesulfonamide analogues as
potent and orally bioavailable microtubule-targeted anticancer
agents. J. Med. Chem. 56, 5562–5586.
Saeed, A., Shaheen, U., Hameed, A., Naqvi, S.Z.H., 2009. Synthesis,
characterization and antimicrobial activity of some new 1-(ﬂuo-
robenzoyl)-3-(ﬂuorophenyl)thioureas. J. Fluorine Chem. 130,
1028–1034.
Salmi, C., Loncle, C., Vidal, N., Letourneux, Y., Brunel, J.M., 2008.
New stereoselective titanium reductive amination synthesis of 3-
amino and polyaminosterol derivatives possessing antimicrobial
activities. Eur. J. Med. Chem. 43, 540–547.
Shan, L.H., Liu, H.M., Huang, K.X., Dai, G.F., Cao, C., Dong, R.J.,
2009. Synthesis of 3b, 7a, 11a-trihydroxy-pregn-21-benzylidene-5-
en-20-one derivatives and their cytotoxic activities. Bioorg. Med.
Chem. Lett. 19, 6637–6639.
Vega-Perez, J.M., Perinan, I., Argandona, M., Vega-Holm, M., Palo-
Nieto, C., Burgos-Moron, E., 2012. Isoprenyl-thiourea and urea
derivatives as new farnesyl diphosphate analogues: synthesis and
in vitro antimicrobial and cytotoxic activities. Eur. J. Med. Chem.
58, 591–612.
Zhao, Y.F., Liu, Z.J., Zhai, X., Ge, D.D., Huang, Q., Gong, P., 2013.
Synthesis and in vitro antitumor activity of novel diaryl urea
derivatives. Chin. Chem. Lett. 24, 386–388.
